B. Riley Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by B. Riley from $9.00 to $7.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley’s target price indicates a potential upside of 222.58% from the company’s previous close.

PDSB has been the topic of several other reports. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Friday, November 15th. Finally, StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Stock Up 3.8 %

Shares of NASDAQ PDSB traded up $0.08 during midday trading on Monday, reaching $2.17. The company’s stock had a trading volume of 148,263 shares, compared to its average volume of 610,344. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.68. The stock has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $3.20. The stock has a market capitalization of $81.18 million, a price-to-earnings ratio of -1.90 and a beta of 1.93. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently bought and sold shares of the company. Tempus Wealth Planning LLC bought a new stake in PDS Biotechnology in the 2nd quarter valued at $55,000. Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology in the second quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth about $115,000. Squarepoint Ops LLC bought a new stake in shares of PDS Biotechnology during the 2nd quarter worth about $120,000. Finally, Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology in the 2nd quarter valued at about $146,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.